Uncovering the signalling, structure and function of the 20-HETE-GPR75 pairing: Identifying the chemokine CCL5 as a negative regulator of GPR75.

Jonathan V Pascale, Eon Joo Park, Adeniyi Michael Adebesin, John R Falck, Michal Laniado Schwartzman, Victor Garcia

Journal: British journal of pharmacology 2021;178(18):3813-3828

PMID: 33974269

Abstract

BACKGROUND AND PURPOSE

The G-protein-coupled receptor GPR75 (Gq) and its ligand, the cytochrome P450-derived vasoactive eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE), are involved in the activation of pro-inflammatory and hypertensive signalling cascades contributing to diabetes, obesity, vascular dysfunction/remodelling, hypertension and cardiovascular disease. Little is known as to how, where and with what affinity 20-HETE interacts with GPR75.

EXPERIMENTAL APPROACH

To better understand the pairing of 20-HETE and its receptor (GPR75), we used surface plasmon resonance (SPR) to determine binding affinity/kinetics. The PRESTO-Tango receptor-ome methodology for GPR75 overexpression was coupled with FLIPR Calcium 6 assays, homogeneous time-resolved fluorescence (HTRF) IP-1 and β-arrestin recruitment assays to determine receptor activation and downstream signalling events.

KEY RESULTS

SPR confirmed 20-HETE binding to GPR75 with an estimated K of 1.56 × 10  M. In GPR75-transfected HTLA cells, 20-HETE stimulated intracellular Ca levels, IP-1 accumulation and β-arrestin recruitment, all of which were negated by known 20-HETE functional antagonists. Computational modelling of the putative ligand-binding pocket and mutation of Thr212 within the putative 20-HETE binding site abolished 20-HETE's ability to stimulate GPR75 activation. Knockdown of GPR75 in human endothelial cells nullified 20-HETE-stimulated intracellular Ca . The chemokine CCL5, a suggested GPR75 ligand, binds to GPR75 (K of 5.85 × 10  M) yet fails to activate GPR75; however, it inhibited 20-HETE's ability to activate GPR75 signalling.

CONCLUSIONS AND IMPLICATIONS

We have identified 20-HETE as a high-affinity ligand for GPR75 and CCL5 as a low-affinity negative regulator of GPR75, providing additional evidence for the deorphanization of GPR75 as a 20-HETE receptor.

© 2021 The British Pharmacological Society.

Address: Department of Pharmacology, New York Medical College School of Medicine, Valhalla, New York, USA.; Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA.; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.